Abstracts

827 – Maternal and Infant Predictors of Mortality in Liveborn Infants in the IMPAACT 2010 (VESTED) Trial

Background The IMPAACT 2010 (VESTED) randomized trial compared dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide fumarate (FTC/TAF); DTG plus FTC/tenofovir disoproxil fumarate (TDF) and efavirenz (EFV)/FTC/TDF initiated during pregnancy among 643 women in 9 countries (predominantly in Africa). Previous analyses showed superior virologic efficacy and pregnancy outcomes with DTG-based compared with EFV-based ART. We conducted an exploratory…

1029 – High Prevalence and Associated Factors of STIs Among Pregnant Women Living With HIV in South Africa

Background Pregnant women living with HIV (PWLHIV) are at elevated risk of adverse maternal and infant outcomes especially when coinfected with sexually transmitted infections (STIs). HIV clinical indicators such as ART use, viral load, and timing of diagnosis are proxies for care engagement and health-seeking behaviours, which may be associated with STI prevalence. We examined…

568 – Virologic Failure to CAB+RPV LAI in Real Life: Resistance and Outcomes in a Large Italian Cohort

Background Although virological failure (VF) with Long-acting injectable (LAI) regimen with cabotegravir (CAB) and rilpivirine (RPV) is rare, it is frequently accompanied by integrase inhibitor (INI) and NNRTI resistance, potentially compromising future ART options. We aimed to characterize real-life CAB+RPV LAI failures, resistance and post-failure outcomes in Italy.  Methods We conducted a retrospective observational cohort study including…

877 – European HIV-1 A6 International Transmission Networks Are Enriched by Migrating Populations

Background HIV-1 sub-subtype A6 propels the growing HIV epidemic in Eastern Europe. Long-lasting migration, including war-related displacement from Ukraine, has introduced this lineage into multiple European countries resulting in expanding transmission dynamics in the region. Here we aimed to provide insight on the international A6 transmission patters across selected European regions including enrichment related to…

1083 – Optimizing Service Delivery for Sex Workers Operating in and Around Birmingham, Alabama

Background Implementing appropriate HIV prevention and treatment services for sex workers (SWs) in the U.S. Deep South is critical, given SWs are disproportionally affected by HIV and face complex barriers to care. Yet community-informed implementation strategies remain limited. Methods Using a convergent mixed methods design, we explored multilevel determinants of HIV program utilization and unmet…

368 – Safety and Antiviral Activity of CD4 Mimetic Treatment in SHIV-Infected Rhesus Macaques

Background CD4 downregulation on HIV-1–infected cells impairs their elimination via ADCC by preventing non-neutralizing antibodies (nnAbs) from binding CD4-induced epitopes in Env. CD4-mimetic compounds (CD4mc) can expose these epitopes and restore ADCC. CJF-III-288 is a small CD4 mimetic compound (mc) that binds within the Phe43 cavity of gp120 “opening-up” Env, thereby allowing CD4-induced (CD4i) nnAbs…

847 – RV534 Trial: T-Cell Responses and HIV Reservoir Change in HIVIS-DNA/MVA-CMDR+TLR4 Vaccinated Youth

Background Therapeutic vaccines offer a promising strategy to boost immune responses, reduce the HIV reservoir and potentially achieve ART-free remission. In this study, we characterized HIV-specific T-cell responses and assessed their correlation with the intact HIV reservoir in the RV534 trial. Methods 25 youths (M/F=13/12; median age=15 years) with perinatal HIV, on ART since 6…

854 – Safety & Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Young Children 10 – < 40 kg

Background Long-acting cabotegravir (CAB-LA) plus long-acting rilpivirine (RPV-LA) are approved for maintenance of viral suppression in adults and adolescents at least 12 years and 35kgs with HIV-1 infection. IMPAACT 2036 (CRAYON) is a Phase I/II study evaluating oral (PO) and intramuscular (IM) CAB-LA+RPV-LA in virologically suppressed children 2-<12 years, with HIV-1. Here, we present all…